PCI Synthesis earns top Life Science Leader awards for second year in a row

Published: 17-Mar-2015
Manufacturing


PCI Synthesis, a pharmaceutical manufacturer of new chemical entities, generic active pharmaceutical ingredients, and other speciality chemical products, has been recognised as a Life Science Leader CMO Leadership Award recipient in the category of Regulatory for the midsize pharma and biotech industry sectors. This is the second year in a row that PCI Synthesis has been awarded multiple CMO Leadership Awards and the company has now won an award in every category in which the awards are given.

 

The CMO Leadership Awards are determined from industry data collected by Nice Insight. Nice Insight conducts an annual survey on pharmaceutical outsourcing practices to collect baseline customer awareness and customer perception of 100+ CMOs and 70+ CROs. Award categories include Quality, Productivity, Reliability, Innovation and Regulatory Record. The annual awards recognise those contract manufacturing organisations (CMOs) that are the most highly rated by industry respondents. This is particularly valuable for pharmaceutical and biopharmaceutical executives in evaluating potential partners for contract manufacturing.

Rob Wright, Chief Editor at Life Science Leader, said: 'The fourth annual CMO Awards recognise the best and the brightest of CMOs in the market today - companies that have earned the respect and trust of executives responsible for making key outsourcing decisions. PCI Synthesis has been an award recipient for two years in a row, a testament to how committed the company is to partnership and high quality products on time and on budget.'

Ed Price, president and CEO of PCI Synthesis, added, 'The importance we place on our relationships with our customers has never been stronger. Through our communication, our commitment to top quality and our investment in best practices, we show our value and work to earn our customers' trust every day.'

  • Companies:
  • Thats Nice
  • Seqens
See more

You may also like

Manufacturing

The US pharmaceutical landscape: growth, innovation and challenges ahead

Read more
The US pharmaceutical market is one of the largest in the world and is experiencing healthy growth owing to its ageing population, the willingness of consumers to spend on healthcare and a high level of investment in R&D, the results of which receive strong intellectual property protection

Trending Articles

  1. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  4. Samsung Biologics bags $668 manufacturing deal with European pharmaceutical company The CDMO will be responsible for the manufacture of the client's biopharmaceuticals until December 2031
  5. CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Manufacturing

The US pharmaceutical landscape: growth, innovation and challenges ahead

The US pharmaceutical market is one of the largest in the world and is experiencing healthy growth owing to its ageing population, the willingness of consumers to spend on healthcare and a high level of investment in R&D, the results of which receive strong intellectual property protection
Manufacturing

Scorpion Biological Services announces new Kansas commercial biomanufacturing facility

Biopharmaceutical contract development and manufacturing organisation Scorpion Biological Services announced a planned development partnership with a private developer, the State of Kansas, and local and university affiliates
Manufacturing

Seqens isopropanol plant expansion

The plant has almost been completed and is due to be finalised as planned by end of Q1 2022
You need to be a subscriber to read this article.
Click here to find out more.
Media

The contract development and manufacturing pulse is steady and strong

Pharma’s CDMOs are sticking to strategic 'fitness' programmes to increase capacity and operational muscle, and compete for elusive market share
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Automating the industrial future of bioprocessing

New drivers are pushing biopharma’s processors to adopt progressive manufacturing strategies at an increasingly aggressive pace
Manufacturing

PCI Synthesis obtains DEA registration for controlled substance development and manufacturing

Certification expands the company's capabilities to handle cGMP development for schedule II, III, IV and V
Manufacturing

Increasing the chances of finding the best possible CRO/CMO fit

Industry research, referrals and consultants remain the top drivers of CRO and CDMO selection, but trade shows are a good way to learn about outsourcing firms and whether their capabilities fit your needs, writes Wei Gao, Director of Accounts, That’s Nice LLC/Nice Insight
Subscribe now